Clinical trials: Advanced Intestinal Cancer, open to volunteers
Advanced Solid Tumor
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid…
- Trial name
- NCT06959615
- Testing
- JAB-23E73
- Where
- 32 sites in China
- Volunteers
- 334 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Rectal Cancer
Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab
This is a single-arm, phase II clinical study aim to evaluate the efficacy and safety of long-term concurrent chemoradiotherapy combined with camrelizumab as a neoadjuvant therapy in the treatment of locally advanced/low rectal…
- Trial name
- NCT06304545
- Testing
- Camrelizumab, Chemotherapy, Radiotherapy
- Volunteers
- 48 people
- Sponsor
- Harbin Medical University
Gastric Cancer, Colorectal Cancer
Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy
This is a prospective observational cohort study conducted at Fundación CTIC in Bogotá, Colombia. It characterizes the oral, fecal and intratumoral microbiome of Colombian adults with advanced solid tumors (gastric, colorectal…
- Conditions
- Gastric Cancer, Colorectal Cancer, Breast Cancer, Cervical Cancer
- Trial name
- ATLAS (NCT07676461)
- Testing
- First-line immunotherapy (immune checkpoint inhibitors), INVIMA-approved, standard of care
- Where
- Colombia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Rectal Cancer, Pelvic Cancer
Advanced Pelvic Surgical Oncology Database - Prospective Observational Study
Retrospective and prospective observational study of patients undergoing advanced pelvic oncological resection for maligancy including multi visceral resection, beyond TME resection and sacrectomy/flap reconstruction/urinary…
- Conditions
- Rectal Cancer, Pelvic Cancer, Gynecologic Cancer, Colon Cancer
- Trial name
- NCT05696002
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Glasgow Royal Infirmary
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Breast Cancer (Locally Advanced or Metastatic), Lymphoma
Remote Monitoring and Symptom Management Digital Application
The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment.
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), Lymphoma, Colorectal Cancer
- Trial name
- ASSIST (NCT07553572)
- Testing
- ASSIST phone application
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Patrick C. Johnson, MD
Anal Squamous Cell Carcinoma
Adaptive Radiation in Anal Cancer
This is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer.
- Trial name
- NCT05838391
- Testing
- Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery, Mitomycin-C, 5-Fluorouracil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Rectal Cancer, Chemotherapy Effect
Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Preoperative radiation with single agent chemotherapy as sensitizer is the standard care of locally advanced rectal cancer. Local irradiation significantly increases surgical complications and impairs quality of life.
- Trial name
- NCT03975049
- Testing
- Chemoradiation, FOLFOXIRI Protocol, Folfox Protocol
- Volunteers
- 933 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Anal Cancer, HPV-Related Carcinoma
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
This study is for people who have anal cancer and have not yet had treatment. The regular treatment for people who have anal cancer is chemoradiation therapy (CRT).
- Conditions
- Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus
- Trial name
- CHART-AC (NCT07425054)
- Testing
- HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Jennifer Dorth
Rectal Neoplasms Malignant, Radiotherapy
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
This phase II/III trial studies how well neoadjuvant short-course radiotherapy and chemotherapy with or without PD-1 inhibitors works in treating patients with locally advanced rectal adenocarcinoma.
- Trial name
- NCT05484024
- Testing
- Sintilimab, Short-course radiotherapy, CAPOX/mFOLFOX
- Where
- 2 sites in China
- Volunteers
- 588 people
- Sponsor
- Chinese Academy of Medical Sciences
Colorectal Cancer, Advanced/Metastatic Solid Tumor
This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with…
- Conditions
- Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM
- Trial name
- NCT07878988
- Testing
- LTZ-232
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- LTZ Therapeutics, Inc.
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Tumor, Solid, Lung Cancer
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Independently developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., CNSI-Fe is an innovative anti-cancer drug with Fe2+ as the active ingredient, which exerts anti-tumor effects by regulating the ferroptosis pathway.
- Conditions
- Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
- Trial name
- NCT07433283
- Testing
- Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron
- Where
- 9 sites in China
- Volunteers
- 54 people
- Sponsor
- Sichuan Enray Pharmaceutical Sciences Company
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
- Conditions
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT07148128
- Testing
- WEF-001
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Auricula Biosciences Inc.
Colorectal Cancer, Pancreatic Cancer
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Trial name
- NCT04421820
- Testing
- BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 220 people
- Sponsor
- Bold Therapeutics, Inc.
Rectal Cancer, Moderately Hypofractionated Radiotherapy
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial
This study aims to observe and evaluate the efficacy and safety of moderately hypofractionated radiotherapy combined with chemotherapy and immunotherapy, compared with conventional neoadjuvant chemoradiotherapy, in patients with…
- Conditions
- Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab, pMMR/MSS
- Trial name
- NCT07527520
- Testing
- Moderately Hypofractionated Radiotherapy, Serplulimab, CapOx+Long-course radiotherapy
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Fudan University
Metastatic Microsatellite-stable Colorectal Cancer
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
This is a randomized, controlled, multicenter phase Ⅲ study to evaluate the therapeutic efficacy and safety of chidamide + sintilimab + bevacizumab versus standard second-line FOLFIRI + bevacizumab therapy in subjects with…
- Trial name
- NCT05768503
- Testing
- Experimental drug, Control Rx
- Where
- 12 sites in China
- Volunteers
- 176 people
- Sponsor
- Sun Yat-sen University
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma
- Trial name
- NCT05733000
- Testing
- Biospecimen Collection, Computed Tomography, Devimistat
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Northwestern University
Rectal Cancer
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant…
- Trial name
- NCT05254327
- Testing
- BMX-001
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- University of Nebraska
Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer
QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer
This is a multicenter, prospective, phase II study evaluating total neoadjuvant therapy (TNT) consisting of short-course radiotherapy (SCRT; 5×5 Gy) followed by QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer
- Trial name
- NCT07175636
- Testing
- Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University